Abstract
Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor (SNRI) that was recently approved by the US Food and Drug Administration for the treatment of fibromyalgia (FM). SNRIs are frequently used, along with graded exercise and cognitive-behavioral therapy, to treat FM. This study evaluated the efficacy and safety of milnacipran in patients with operationally defined FM who did not have a major depressive disorder.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call